The Risk and Burden of Thromboembolic and Hemorrhagic Events in Patients with Malignant Gliomas Receiving Bevacizumab

Overview

Journal J Neurooncol

Publisher Springer

Date 2024 Feb 19

PMID 38372903

Authors

Pushan Dasgupta

Alexander Ou

Heather Lin

Timothy Gregory

Kristin D Alfaro-Munoz

Ying Yuan

Vahid Afshar-Khargan

Carlos Kamiya-Matsuoka

Justin F Rousseau

Nazanin K Majd

Affiliations

Soon will be listed here.

Abstract

Purpose: Bevacizumab has evolved as an integral treatment option for patients with high-grade gliomas. Little is known about clinical risk factors that predispose patients with high-grade gliomas receiving bevacizumab to VTE or ICH. We sought to characterize the clinical risk factors associated with risk of either event.

Methods: In this multi-institutional retrospective study, we first evaluated patients with high-grade gliomas who were treated with bevacizumab at University of Texas MD Anderson Cancer Center from 2015-2021. We compared clinical and treatment-related factors among three cohorts: those who developed VTE, ICH, or neither. We further compared survival outcomes of these patients from the time of bevacizumab initiation. Then to further confirm our results in a non-cancer center hospital setting we evaluated patients from two Ascension Seton Hospitals in Austin, Texas which are affiliated with Dell Medical School at the University of Texas at Austin from 2017-2022.

Results: We found that the presence of cerebral macrobleeding, defined as a magnetic susceptibility of > 1 cm on magnetic resonance imaging, was highly associated with risk of developing ICH after initiation of bevacizumab. Development of ICH was significantly associated with poorer survival outcomes. We did not find a statistically significant effect of VTE on survival after bevacizumab initiation.

Conclusion: In order to stratify the risk for developing ICH before the initiation of bevacizumab, we recommend to assess for the presence of cerebral macrobleeding as it is associated with ICH development.

References

Mir Seyed Nazari P, Riedl J, Preusser M, Posch F, Thaler J, Marosi C . Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism. J Thromb Haemost. 2018; 16(6):1121-1127. PMC: 6099350. DOI: 10.1111/jth.14129. View

Friedman H, Prados M, Wen P, Mikkelsen T, Schiff D, Abrey L . Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27(28):4733-40. DOI: 10.1200/JCO.2008.19.8721. View

Simanek R, Vormittag R, Hassler M, Roessler K, Schwarz M, Zielinski C . Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol. 2007; 9(2):89-95. PMC: 1871666. DOI: 10.1215/15228517-2006-035. View

Kamiya-Matsuoka C, Hamza M, de Groot J . Impact of adverse events of bevacizumab on survival outcomes of patients with recurrent glioblastoma. J Clin Neurosci. 2020; 74:36-40. DOI: 10.1016/j.jocn.2020.01.066. View

Lin X, Daras M, Pentsova E, Nolan C, Gavrilovic I, DeAngelis L . Bevacizumab in high-grade glioma patients following intraparenchymal hemorrhage. Neurooncol Pract. 2019; 4(1):24-28. PMC: 6479824. DOI: 10.1093/nop/npw008. View

Zwicker J, Karp Leaf R, Carrier M . A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation. J Thromb Haemost. 2016; 14(9):1736-40. DOI: 10.1111/jth.13387. View

Porfidia A, Giordano M, Sturiale C, DArrigo S, Donadini M, Olivi A . Risk of intracranial bleeding in patients with primary brain cancer receiving therapeutic anticoagulation for venous thromboembolism: A meta-analysis. Brain Behav. 2020; 10(6):e01638. PMC: 7303369. DOI: 10.1002/brb3.1638. View

Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I . Lomustine and Bevacizumab in Progressive Glioblastoma. N Engl J Med. 2017; 377(20):1954-1963. DOI: 10.1056/NEJMoa1707358. View

Lee I, Adimadhyam S, Nutescu E, Zhou J, Asfaw A, Sweiss K . Bevacizumab Use and the Risk of Arterial and Venous Thromboembolism in Patients with High-Grade Gliomas: A Nested Case-Control Study. Pharmacotherapy. 2019; 39(9):921-928. PMC: 7395667. DOI: 10.1002/phar.2310. View

10.

Lim G, Ho C, Roldan Urgoti G, Leugner D, Easaw J . Risk of Venous Thromboembolism in Glioblastoma Patients. Cureus. 2018; 10(5):e2678. PMC: 6059517. DOI: 10.7759/cureus.2678. View

11.

Mantia C, Uhlmann E, Puligandla M, Weber G, Neuberg D, Zwicker J . Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin. Blood. 2017; 129(25):3379-3385. DOI: 10.1182/blood-2017-02-767285. View

12.

Tawil N, Bassawon R, Meehan B, Nehme A, Montermini L, Gayden T . Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles. Blood Adv. 2021; 5(6):1682-1694. PMC: 7993100. DOI: 10.1182/bloodadvances.2020002998. View

12.

. Abstracts from the 20th International Conference on Brain Tumor Research and Therapy, July 20-22, 2014, Lake Tahoe, California. Neuro Oncol. 2014; 16 Suppl 3:iii1-52. PMC: 4144473. DOI: 10.1093/neuonc/nou206.1. View

13.

Alkhachroum A, Bustillo A, Asdaghi N, Marulanda-Londono E, Gutierrez C, Samano D . Withdrawal of Life-Sustaining Treatment Mediates Mortality in Patients With Intracerebral Hemorrhage With Impaired Consciousness. Stroke. 2021; 52(12):3891-3898. PMC: 8608746. DOI: 10.1161/STROKEAHA.121.035233. View

14.

Chinot O, de La Motte Rouge T, Moore N, Zeaiter A, Das A, Phillips H . AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther. 2011; 28(4):334-40. DOI: 10.1007/s12325-011-0007-3. View

15.

Khoury M, Missios S, Edwin N, Sakruti S, Barnett G, Stevens G . Intracranial hemorrhage in setting of glioblastoma with venous thromboembolism. Neurooncol Pract. 2019; 3(2):87-96. PMC: 6668262. DOI: 10.1093/nop/npv028. View

16.

Thaler J, Ay C, Kaider A, Reitter E, Haselbock J, Mannhalter C . Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas. Neuro Oncol. 2014; 16(12):1645-51. PMC: 4232082. DOI: 10.1093/neuonc/nou106. View

17.

Nabi S, Kahlon P, Bozorgnia F, Arshad A, Mikkelsen T, Donthireddy V . Predictors of Venous Thromboembolism in Patients with Glioblastoma. Pathol Oncol Res. 2015; 22(2):311-6. DOI: 10.1007/s12253-015-0008-7. View

18.

Taal W, Oosterkamp H, Walenkamp A, Dubbink H, Beerepoot L, Hanse M . Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014; 15(9):943-53. DOI: 10.1016/S1470-2045(14)70314-6. View

19.

Streiff M, Segal J, Grossman S, Kickler T, Weir E . ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas. Cancer. 2004; 100(8):1717-23. DOI: 10.1002/cncr.20150. View